Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NALT1 (NOTCH1 associated long non-coding RNA in T cell acute lymphoblastic leukemia 1) is a long non-coding RNA gene located upstream of NOTCH1 within 10 kb, identified as playing an oncogenic role in pediatric T-ALL[3][1]. It is upregulated in T-ALL patient samples, and its increased expression correlates with upregulation of NOTCH1. NALT1 is nuclear-localized and acts as a transcriptional activator for the NOTCH1 gene, thereby enhancing NOTCH1 pathway activity and promoting leukemic cell proliferation[1]. Downregulation of NALT1 decreases both NOTCH1 expression and proliferation of T-ALL cells. Targeting the NOTCH signaling pathway through gamma secretase inhibitors reduces the proliferation promoted by NALT1, indicating that NALT1 promotes leukemogenesis predominantly through activation of the NOTCH1 signaling cascade[1]. NALT1 is therefore considered a key regulatory lncRNA in the NOTCH1 pathway and an emerging molecular target for pediatric T-ALL therapy.
Inhibition of NOTCH1 signaling pathway via gamma secretase inhibition (for GSIs targeting the pathway activated by this lncRNA)[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NOTCH1 associated long non-coding RNA in T cell acute lymphoblastic leukemia 1 (NALT1).